Kenichiro Ishii1,2, Izumi Matsuoka1, Shinya Kajiwara1, Takeshi Sasaki1, Manabu Miki1, Manabu Kato1, Hideki Kanda1, Kiminobu Arima1, Taizo Shiraishi3, Yoshiki Sugimura4. 1. Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. 2. Department of Oncologic Pathology, Mie University Graduate School of Medicine, Tsu, Mie, Japan. 3. Department of Diagnostic Pathology, Kuwana City Medical Center, Kuwana, Mie, Japan. 4. Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. sugimura@clin.medic.mie-u.ac.jp.
Abstract
PURPOSE: Docetaxel (DTX) is a standard chemotherapeutic drug for castration-resistant prostate cancer (CRPC), although adverse events are common. To overcome this problem, researchers have evaluated the efficacy of DTX treatment in combination with other drugs. Naftopidil is a tubulin-binding drug with fewer adverse events, implying the usefulness of this drug in clinical applications when combined with DTX. Here, we investigated the efficacy of additive naftopidil treatment in combination with DTX on prostate cancer (PCa) cells. METHODS: The effects of combination treatment with DTX plus naftopidil were analyzed using two animal models of LNCaP cells plus PrSC xenografts (sub-renal capsule grafting) and PC-3 xenografts (intratibial injection). RESULTS: Combination treatment with DTX plus naftopidil significantly inhibited cell growth in LNCaP cells compared with DTX alone. Analysis of the cooperativity index (CI) showed that combination treatment exhibited additive effects on DTX-induced growth inhibition in LNCaP cells. In contrast, combination treatment showed more than an additive (synergistic) effect on DTX-induced apoptosis in LNCaP and PC-3 cells. In LNCaP cells plus PrSC xenografts, combination treatment showed synergistic effects on DTX-induced apoptosis. The synergistic effects of naftopidil on DTX-induced apoptosis were also observed in PC-3 xenografts. CONCLUSIONS: Our results demonstrated that additive naftopidil treatment in combination with DTX increased the efficacy of DTX for the treatment of LNCaP and PC-3 tumors in vivo. Thus, additive naftopidil treatment showed a synergistic effect on DTX-induced apoptosis in PCa cells in vitro and in vivo, suggesting that this treatment approach may yield improved clinical benefits compared with DTX alone.
PURPOSE:Docetaxel (DTX) is a standard chemotherapeutic drug for castration-resistant prostate cancer (CRPC), although adverse events are common. To overcome this problem, researchers have evaluated the efficacy of DTX treatment in combination with other drugs. Naftopidil is a tubulin-binding drug with fewer adverse events, implying the usefulness of this drug in clinical applications when combined with DTX. Here, we investigated the efficacy of additive naftopidil treatment in combination with DTX on prostate cancer (PCa) cells. METHODS: The effects of combination treatment with DTX plus naftopidil were analyzed using two animal models of LNCaP cells plus PrSC xenografts (sub-renal capsule grafting) and PC-3 xenografts (intratibial injection). RESULTS: Combination treatment with DTX plus naftopidil significantly inhibited cell growth in LNCaP cells compared with DTX alone. Analysis of the cooperativity index (CI) showed that combination treatment exhibited additive effects on DTX-induced growth inhibition in LNCaP cells. In contrast, combination treatment showed more than an additive (synergistic) effect on DTX-induced apoptosis in LNCaP and PC-3 cells. In LNCaP cells plus PrSC xenografts, combination treatment showed synergistic effects on DTX-induced apoptosis. The synergistic effects of naftopidil on DTX-induced apoptosis were also observed in PC-3 xenografts. CONCLUSIONS: Our results demonstrated that additive naftopidil treatment in combination with DTX increased the efficacy of DTX for the treatment of LNCaP and PC-3 tumors in vivo. Thus, additive naftopidil treatment showed a synergistic effect on DTX-induced apoptosis in PCa cells in vitro and in vivo, suggesting that this treatment approach may yield improved clinical benefits compared with DTX alone.
Authors: Yang-Min Ning; James L Gulley; Philip M Arlen; Sukyung Woo; Seth M Steinberg; John J Wright; Howard L Parnes; Jane B Trepel; Min-Jung Lee; Yeong Sang Kim; Haihao Sun; Ravi A Madan; Lea Latham; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Andrew M Harris; Bradley W Warner; John M Wilson; Aaron Becker; Randall G Rowland; William Conner; Matthew Lane; Kimberly Kimbler; Eric B Durbin; Andre T Baron; Natasha Kyprianou Journal: J Urol Date: 2007-09-17 Impact factor: 7.450
Authors: Ulka N Vaishampayan; Shanthi Marur; Lance K Heilbrun; Michael L Cher; Brenda Dickow; Daryn W Smith; Samir A Al Hasan; James Eliason Journal: J Urol Date: 2009-05-17 Impact factor: 7.450
Authors: Xia-Wen Liu; Yi Rong; Xing-Fei Zhang; Jun-Jun Huang; Yi Cai; Bi-Yun Huang; Liu Zhu; Bo Wu; Ning Hou; Cheng-Feng Luo Journal: Front Pharmacol Date: 2018-01-11 Impact factor: 5.810